Pyxis Oncology, Inc. (PYXS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 6M 12M 18M Q1 '24: 16.1M Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 2.8M Q3 '25: 0 Q4 '25: 11M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Gross Profit Quarterly

0 6M 12M 18M Q1 '24: 15.7M Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '24 Q2 '24 Q3 '24 Q4 '24

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -11.6M Q4 '21: -16.4M Q1 '22: -31.4M Q2 '22: -25.7M Q3 '22: -28.4M Q4 '22: -38M Q1 '23: -21M Q2 '23: -18.1M Q3 '23: -25.4M Q4 '23: -17.8M Q1 '24: -5.6M Q2 '24: -20M Q3 '24: -23.8M Q4 '24: -40.1M Q1 '25: -22.9M Q2 '25: -19.8M Q3 '25: -23.5M Q4 '25: -18.3M Q1 '26: -24.4M Q2 '26: -26M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -14.2M Q4 '21: -16.8M Q1 '22: -31.4M Q2 '22: -25.6M Q3 '22: -27.7M Q4 '22: -36.1M Q1 '23: -19.2M Q2 '23: -15.9M Q3 '23: -23M Q4 '23: -15.6M Q1 '24: -3.3M Q2 '24: -17.3M Q3 '24: -21.2M Q4 '24: -35.6M Q1 '25: -21.2M Q2 '25: -18.4M Q3 '25: -22M Q4 '25: -18.1M Q1 '26: -23.3M Q2 '26: -25.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 200K 400K 600K Q1 '24: 475K Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '24 Q2 '24 Q3 '24 Q4 '24

Operating Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '21: -7.3M Q4 '21: -12.2M Q1 '22: -27.7M Q2 '22: -23.7M Q3 '22: -20.6M Q4 '22: -17.4M Q1 '23: -26.8M Q2 '23: -11M Q3 '23: -17.6M Q4 '23: -15.3M Q1 '24: -20.7M Q2 '24: -3M Q3 '24: -14.7M Q4 '24: -19.3M Q1 '25: -22.5M Q2 '25: -17.3M Q3 '25: -13.3M Q4 '25: -10.4M Q1 '26: -26M Q2 '26: -18.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q4 '20: -3.2M Q1 '21: -18.9M Q2 '21: 2.5M Q3 '21: -7.3M Q4 '21: -12.2M Q1 '22: -27.8M Q2 '22: -23.8M Q3 '22: -24.8M Q4 '22: -19.2M Q1 '23: -31.2M Q2 '23: -13.3M Q3 '23: -17.6M Q4 '23: -15.3M Q1 '24: -20.9M Q2 '24: -3M Q3 '24: -14.7M Q4 '24: -19.3M Q4 '25: -10.4M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '21: 1.5M Q3 '21: 1.6M Q1 '22: 32.3M Q2 '22: 32.5M Q3 '22: 32.6M Q1 '23: 35.4M Q2 '23: 38.4M Q3 '23: 41.3M Q1 '24: 51.3M Q2 '24: 60.5M Q3 '24: 60.7M Q1 '25: 61M Q2 '25: 61.9M Q3 '25: 62.6M Q1 '26: 63.5M Q2 '26: 64M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q3 '21: -45.78 Q4 '21: -8.95 Q1 '22: 17.34 Q2 '22: 22.09 Q3 '22: 30.20 Q4 '22: -3.65 Q1 '23: -3.22 Q2 '23: -2.84 Q3 '23: -2.55 Q4 '23: -1.84 Q1 '24: -1.36 Q2 '24: -1.24 Q3 '24: -1.03 Q4 '24: -1.29 Q1 '25: -1.58 Q2 '25: -1.59 Q3 '25: -1.59 Q4 '25: -1.29 Q1 '26: -1.31 Q2 '26: -1.41 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.